Ozempic, Wegovy, Mounjaro, Zepbound: Which Wins?

Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through partner links, at no extra cost to you. Editorial independence preserved — recommendations based on provider compliance and patient outcomes, not commission rates. This article is informational and is not medical advice; talk to a licensed clinician before starting, stopping or switching any medication.

Ozempic, Wegovy, Mounjaro, Zepbound — four of the most searched drug names in the world, and four names people constantly mix up. Some assume all four compete head to head; others assume any two are interchangeable. Both ideas are wrong, and the reality is simpler than the marketing makes it look. This guide lays out what each brand actually is, what the FDA has approved it to do, how the two underlying drugs compare on weight loss and heart protection, how they are dosed, and what they cost in 2026.

Same Drug, Different Brand

Start with the single fact that clears up most of the confusion: the four brands are built on just two drugs, made by two companies.

Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. Within each pair the diabetes brand and the weight-loss brand are the identical drug — they differ in approved use, dosing and price, not in chemistry. Drugmakers split one drug into two brands because the FDA approves medications for specific indications and insurers cover them that way: a separate weight-loss brand can carry its own label, its own trial program and its own pricing, and a health plan can cover the diabetes version without automatically covering the obesity one. So the real question is never four-way. It is semaglutide versus tirzepatide, seen through whichever brand fits your situation.

Each drug now also comes as a daily tablet — Rybelsus and the newer Ozempic tablets for type 2 diabetes, the Wegovy oral tablet for weight management; our complete Rybelsus guide covers the oral semaglutide options. The four injectable brands below are what most people are actually weighing up.

Semaglutide vs Tirzepatide: Why the Two Drugs Differ

The brand split is a labeling exercise. The two drugs themselves are genuinely different, and that difference drives most of what follows.

Semaglutide — the drug in Ozempic and Wegovy — is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that triggers glucose-dependent insulin release, suppresses glucagon, slows stomach emptying and dampens appetite signaling in the brain. It works through one receptor pathway. Tirzepatide — the drug in Mounjaro and Zepbound — is a dual agonist: it activates the GLP-1 receptor and also the GIP (glucose-dependent insulinotropic polypeptide) receptor, a second incretin hormone. Engaging both pathways appears to produce a larger metabolic effect than GLP-1 alone, and tirzepatide was the first dual GIP/GLP-1 agonist to reach the market.

That mechanism gap is the reason tirzepatide tends to outperform semaglutide on weight and blood sugar in clinical trials. It does not make tirzepatide the right choice for everyone — indication match, tolerability, cost and a clinician’s judgment all weigh in — but it is a real pharmacological difference, not a marketing one.

What Each Brand Is Approved For

This is where the four brands genuinely separate. Each carries its own set of FDA-approved uses, and they overlap less than people expect.

The table holds a few surprises worth stating plainly. Wegovy carries a cardiovascular indication — based on the SELECT trial it is approved to cut the risk of major cardiac events in adults with established heart disease and obesity or overweight — but Zepbound, the stronger weight-loss drug, does not. Zepbound, in turn, is the only one of the four approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, which Wegovy is not. Ozempic adds a kidney indication, slowing chronic kidney disease progression in type 2 diabetes. And Mounjaro has the narrowest label of the group: type 2 diabetes glycemic control only, with no weight-management or cardiovascular indication.

Mounjaro’s cardiovascular status is worth a closer look, because the evidence shifted recently. In December 2025 the SURPASS-CVOT trial — tirzepatide’s first dedicated cardiovascular outcomes study — was published in the New England Journal of Medicine. In more than 13,000 patients with type 2 diabetes and established heart disease, followed for a median of four years, tirzepatide was compared against dulaglutide, Lilly’s older GLP-1 sold as Trulicity. It met the bar for non-inferiority — no worse than dulaglutide for major cardiac events — but missed the separate, higher bar for superiority: the roughly 8% relative reduction in events was not statistically significant. That gives Mounjaro solid cardiovascular safety evidence, but not the superiority result behind Ozempic’s and Wegovy’s heart indications. Lilly is expected to seek a cardiovascular indication; as of May 2026 the FDA has not granted one.

Which One Loses More Weight?

For weight loss the relevant brands are Wegovy and Zepbound — the two approved for it. Here is what the trials show.

The result that carries the most weight is SURMOUNT-5, because it is the only direct head-to-head trial. It randomized 751 adults with obesity and no diabetes to tirzepatide or semaglutide at maximum tolerated doses, and followed them for 72 weeks. Tirzepatide produced a mean weight loss of 20.2% against 13.7% for semaglutide — roughly 47% greater — and about 31.6% of the tirzepatide group lost at least a quarter of their body weight, versus about 16.1% on semaglutide. Like for like, tirzepatide won that trial clearly.

One caveat keeps that honest. SURMOUNT-5 used semaglutide at its 2.4 mg maximum, the highest Wegovy dose available when the trial ran. In March 2026 the FDA approved Wegovy HD, a 7.2 mg semaglutide dose, after the STEP UP trial showed a mean weight loss of about 21% over 72 weeks versus roughly 16% on the 2.4 mg dose in the same trial. No trial has yet pitted 7.2 mg semaglutide directly against tirzepatide, so the gap at each drug’s top dose is not settled — the higher Wegovy dose narrows it, but by how much remains untested.

Two things stay true regardless. Both drugs produce weight loss far beyond anything older medications achieved — even the lower semaglutide figure is clinically substantial. And the averages hide enormous individual variation: tolerability, not the trial mean, often decides which drug a given person can actually stay on long enough to benefit.

Heart and Kidney Protection

Beyond weight and blood sugar, these drugs are increasingly judged on whether they protect the heart and kidneys — and here the semaglutide brands hold the stronger regulatory hand. Ozempic is approved both to reduce major cardiac events in type 2 diabetes with established heart disease, supported by the SUSTAIN-6 trial, and to slow chronic kidney disease progression, supported by the FLOW trial. Wegovy’s cardiovascular indication rests on SELECT, which enrolled more than 17,000 patients with heart disease and obesity or overweight but not diabetes, and showed roughly a 20% reduction in major cardiac events. Mounjaro, as covered above, has cardiovascular safety data from SURPASS-CVOT but no indication. Zepbound has no cardiovascular indication at all — its distinguishing extra approval is for sleep apnea. If organ protection is a primary reason a drug is being considered, that currently points toward Ozempic or Wegovy, the two brands carrying an FDA-approved cardiovascular indication.

How They Are Dosed

All four are once-weekly subcutaneous injections, and all four are titrated — started low and stepped up gradually to limit nausea and let the body adjust. The dose ladders differ:

• Ozempic: started at 0.25 mg weekly, stepped up through 0.5 mg and 1 mg, to a 2 mg maximum.
• Wegovy: started at 0.25 mg weekly and stepped up through 0.5 mg, 1 mg and 1.7 mg to a 2.4 mg maintenance dose — with the 7.2 mg Wegovy HD option available only after at least four weeks of tolerating the 2.4 mg dose.
• Mounjaro and Zepbound: both use the same tirzepatide ladder — started at 2.5 mg weekly, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, to a 15 mg maximum.

Titration is not optional fine print — stepping up too quickly is a common, avoidable cause of severe nausea — and the starter dose is generally not the dose behind the headline weight-loss numbers. Those come from the maintenance doses, reached over roughly two months, which is also the price point to budget around.

Side Effects and Tolerability

All four drugs share a broadly similar side-effect profile, because all four act largely through the GLP-1 pathway. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, constipation and abdominal discomfort. These are usually mild to moderate, most pronounced during dose escalation, and tend to ease as the body adapts; slow titration and dietary adjustments are the standard ways to manage them.

Less common but more serious risks listed across this drug class include pancreatitis and gallbladder problems, plus — based on rodent studies — a boxed warning regarding a risk of thyroid C-cell tumors; the drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. In the head-to-head SURMOUNT-5 trial, gastrointestinal side effects leading to discontinuation were actually somewhat more common on semaglutide than on tirzepatide, though both were generally well tolerated. Tolerability is highly individual, the serious risks are shared across the class, and the decision to start, switch or stop belongs with a prescribing clinician who knows your history.

What They Cost in 2026

List prices for all four brands sit in a similar range — roughly $1,000 to $1,350 a month before insurance. As of May 2026, Ozempic’s list price is around $1,028 a month, Mounjaro’s is roughly $1,069–$1,079, Zepbound’s is roughly $1,086–$1,088, and Wegovy’s is around $1,349. Almost nobody pays those numbers, though.

If a drug is covered by insurance for an approved indication, the out-of-pocket cost is just a copay. If it is not covered, 2026 has produced a genuine spread of cash-pay options: manufacturer self-pay programs (Novo Nordisk’s NovoCare for Ozempic and Wegovy, LillyDirect for Zepbound), the federal TrumpRx platform, retail cash discounts, and compounded semaglutide. Self-pay brand pricing now commonly runs a few hundred dollars a month rather than four figures. Coverage tends to be easier to get for the diabetes brands, Ozempic and Mounjaro, than for the weight-management brands, Wegovy and Zepbound, which insurers more often exclude or gate behind prior authorization. For a full breakdown of every route and current numbers, see our complete 2026 GLP-1 cost guide.

Which One Fits Your Situation?

The right brand follows from your situation, not from which name you have heard most. A few common cases:

• You have type 2 diabetes. The relevant brands are Ozempic and Mounjaro. Tirzepatide tends to deliver greater glycemic and weight improvement; Ozempic carries the cardiovascular and kidney indications. Coverage and your clinician’s read of your cardiac and renal risk usually decide.
• Weight loss is the main goal. The relevant brands are Wegovy and Zepbound. In the head-to-head trial Zepbound’s drug, tirzepatide, produced greater average weight loss — but Wegovy is the one with an approved cardiovascular indication, which matters if you also have established heart disease.
• You have obesity and obstructive sleep apnea. Zepbound is the only one of the four with an FDA-approved sleep-apnea indication.
• Cost is the deciding factor. Check insurance coverage first; if you are paying cash, compare the manufacturer self-pay programs, TrumpRx and compounded semaglutide, all covered in the cost guide linked above.

None of these cases is a do-it-yourself decision. Indication match, your medical history, insurance, tolerability and drug availability all feed into the choice, and a prescriber weighs them together. Use this comparison to walk into that conversation informed.

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Both contain semaglutide and are made by Novo Nordisk. The difference is the approved use and the dose ladder: Ozempic is approved for type 2 diabetes and tops out at 2 mg weekly, while Wegovy is approved for chronic weight management, runs to a 2.4 mg maintenance dose, and now has a 7.2 mg high-dose option. Insurers also treat them differently — diabetes coverage for Ozempic is more common than obesity coverage for Wegovy.

Is Mounjaro or Zepbound better for weight loss?

Both are tirzepatide, so the weight-loss effect of the drug is identical. Only Zepbound is FDA-approved for chronic weight management; Mounjaro is approved for type 2 diabetes. If weight loss is the goal, Zepbound is the brand approved and prescribed for it — though a clinician treating diabetes may still choose Mounjaro, with weight loss as a secondary benefit.

Which GLP-1 produces the most weight loss?

In the only head-to-head trial, SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide — about 20.2% versus 13.7% over 72 weeks. That trial used the 2.4 mg semaglutide dose; the newer 7.2 mg high-dose semaglutide narrows the gap but has not been tested directly against tirzepatide. Individual results vary widely regardless of which drug is used.

Can you switch between these medications?

Switching — for example from semaglutide to tirzepatide, or from a diabetes brand to the matching weight-loss brand — is done in clinical practice, but it is a prescriber’s decision. A switch usually means restarting titration at a low dose of the new drug rather than matching the old dose directly. Never switch GLP-1 medications on your own.

Which of these are approved for heart health?

Ozempic and Wegovy both carry FDA-approved cardiovascular risk-reduction indications. Mounjaro does not — its SURPASS-CVOT trial showed cardiovascular non-inferiority to dulaglutide but not superiority, and no cardiovascular indication had been granted as of May 2026. Zepbound has no cardiovascular indication; its extra indication is for obstructive sleep apnea.

Are there cheaper alternatives to these brand drugs?

For semaglutide, compounded semaglutide from a licensed 503A pharmacy is typically the lowest-cost route — the same active drug as Ozempic and Wegovy, though not an FDA-approved finished product. Manufacturer self-pay programs and the TrumpRx platform have also brought brand cash prices well below list. Our 2026 cost guide breaks down every option in detail.

The Bottom Line

The comparison is simpler than the four brand names suggest. Two drugs are in play: semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, and tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss. Tirzepatide’s dual mechanism tends to produce greater weight loss — confirmed in the one head-to-head trial — while the semaglutide brands currently hold the cardiovascular and kidney indications. The right pick depends on whether you are treating diabetes or obesity, whether heart disease or sleep apnea is in the picture, how each option is covered, and what you can tolerate. Bring this map to a clinician — the final call is a medical one.

Clinical and pricing details in this article reflect publicly reported information as of May 2026 and can change. Confirm any drug indication, dose or price with a licensed clinician, the manufacturer or the pharmacy before making a decision.